CD274 and non-small cell lung carcinoma: In this study, we longitudinally evaluated the change in the number of CTCs and PD-L1 positivity rates in CTCs from 44 advanced NSCLC patients who received nivolumab treatment and analyzed the correlation between clinical findings and CTC status.